IPHA vs BIIB: Which Stock is Better?
Side-by-side comparison of Innate Pharma Sa and Biogen Inc in 2026
IPHA
Innate Pharma Sa
$1.69
BIIB
Biogen Inc
$180.54
Key Metrics Comparison
| Metric | IPHA | BIIB | Winner |
|---|---|---|---|
| Market Cap | $152.94M | $26.50B | BIIB |
| P/E Ratio | N/A | 20.54 | BIIB |
| EPS (TTM) | $N/A | $8.79 | BIIB |
| Revenue Growth | -0.5% | -0.1% | BIIB |
| Gross Margin | -384.4% | 78.9% | BIIB |
Analyze IPHA
Full quant analysis
Analyze BIIB
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is IPHA or BIIB a better investment?
Comparing IPHA and BIIB: Innate Pharma Sa has a market cap of $152.94M while Biogen Inc has $26.50B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between IPHA and BIIB?
IPHA (Innate Pharma Sa) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: IPHA or BIIB?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: IPHA or BIIB?
BIIB has higher revenue growth at -0.1% vs -0.5% for IPHA.
Which company is more profitable: IPHA or BIIB?
Biogen Inc (BIIB) has higher gross margins at 78.9% compared to -384.4% for IPHA.
Which is the larger company: IPHA or BIIB?
Biogen Inc (BIIB) is larger with a market cap of $26.50B compared to $152.94M for IPHA.
Should I buy IPHA or BIIB in 2026?
Both IPHA and BIIB have investment merit. IPHA trades at $1.69 while BIIB trades at $180.54. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between IPHA and BIIB stock?
Key differences: Market Cap ($152.94M vs $26.50B), P/E Ratio (N/A vs 20.5x), Revenue Growth (-0.5% vs -0.1%), Gross Margin (-384.4% vs 78.9%).